PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Genetic diseases • Non-genetic diseases • Market opportunity by application PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas • EMEA • APAC • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Increasing number of research activities on human genomics • Growing technological improvements in DNA sequencing • Increasing M&A PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Agilent Technologies • BGI • F. Hoffmann-La Roche • Illumina • Laboratory Corporation of America • Natera • Other prominent vendors PART 15: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global DNA sequencing market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global prenatal DNA sequencing market 2017-2022 ($ mn) Exhibit 09: Global prenatal DNA sequencing market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Market condition - Five forces 2022 Exhibit 19: Global prenatal DNA sequencing market by application – Market share 2017-2022 (%) Exhibit 20: Comparison by application Exhibit 21: Common types of genetic disorders Exhibit 22: Global prenatal DNA sequencing market by genetic diseases – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global prenatal DNA sequencing market by genetic diseases – Year-over-year growth 2018-2022 (%) Exhibit 24: Global prenatal DNA sequencing market by non-genetic diseases – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global prenatal DNA sequencing market by non-genetic diseases – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Global – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: R&D funding for cancer 2013-2016 ($ millions) Exhibit 41: Cost of sequencing per genome 2001-2015 ($) Exhibit 42: Prominent M&A in DNA sequencing market 2007-2014 Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Agilent Technologies overview Exhibit 49: Agilent Technologies – Business segments Exhibit 50: Agilent Technologies – Organizational developments Exhibit 51: Agilent Technologies – Geographic focus Exhibit 52: Agilent Technologies – Segment focus Exhibit 53: Agilent Technologies – Key offerings Exhibit 54: BGI: Overview Exhibit 55: BGI: Business segments Exhibit 56: BGI: Organizational developments Exhibit 57: BGI: Geographic focus Exhibit 58: BGI: Segment focus Exhibit 59: BGI: Key offerings Exhibit 60: F. Hoffmann-La Roche: Overview Exhibit 61: F. Hoffmann-La Roche: Business segments Exhibit 62: F. Hoffmann-La Roche: Organizational developments Exhibit 63: F. Hoffmann-La Roche: Geographic focus Exhibit 64: F. Hoffmann-La Roche: Segment focus Exhibit 65: F. Hoffmann-La Roche: Key offerings Exhibit 66: Illumina: Overview Exhibit 67: Illumina: Business segments Exhibit 68: Illumina: Organizational developments Exhibit 69: Illumina: Geographic focus Exhibit 70: Illumina: Segment focus Exhibit 71: Illumina: Key offerings Exhibit 72: Laboratory Corporation of America overview Exhibit 73: Laboratory Corporation of America – Business segments Exhibit 74: Laboratory Corporation of America– Organizational developments Exhibit 75: Laboratory Corporation of America – Geographic focus Exhibit 76: Laboratory Corporation of America – Segment focus Exhibit 77: Laboratory Corporation of America– Key offerings Exhibit 78: Natera overview Exhibit 79: Natera – Business segments Exhibit 80: Natera– Organizational developments Exhibit 81: Natera – Geographic focus Exhibit 82: Natera – Segment focus Exhibit 83: Natera – Key offerings

Agilent Technologies BGI F. Hoffmann-La Roche Illumina Laboratory Corporation of America Natera Other prominent vendors